New Hope For Dermatitis Patients Amidst This New Drug Development

Connect Biopharma Announces Promising Trial Results for Rademikibart: A Potential Game-Changer for Atopic Dermatitis Patients.

In a significant development in the healthcare sector, Connect Biopharma has announced positive long-term data from the China Pivotal Trial of their innovative drug, Rademikibart, in patients with moderate-to-severe Atopic Dermatitis. This breakthrough could potentially change the lives of millions of patients worldwide who suffer from this chronic skin…